Genetically predicted C-reactive protein associated with breast cancer risk: interrelation with estrogen and cancer molecular subtypes using a Mendelian randomization

Su Yon Jung (sjung@sonnet.ucla.edu)
University of California Los Angeles

Jeanette C. Papp
University of California Los Angeles

Eric M. Sobel
University of California Los Angeles

Matteo Pellegrini
University of California Los Angeles

Herbert Yu
University of Hawai‘i Cancer Center

Zuo-Feng Zhang
University of California Los Angeles

Research article

Keywords: genetically driven C-reactive protein, Mendelian randomization, obesity, exogenous estrogen, breast cancer subtypes by hormone receptor and HER2/neu.

DOI: https://doi.org/10.21203/rs.3.rs-57683/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Immune-related etiologic pathways that influence breast cancer risk are incompletely understood and may be confounded by lifestyles or reverse causality. Using a Mendelian randomization (MR) approach, we investigated the potential causal relationship between genetically elevated C-reactive protein (CRP) concentrations and primary invasive breast cancer risk in postmenopausal women.

**Methods:** We used individual-level data obtained from 10,170 women, including 537 who developed breast cancer, from the Women’s Health Initiative Database for Genotypes and Phenotypes Study, which consists of 5 genome-wide association (GWA) studies. We examined 61 GWA single-nucleotide polymorphisms (SNPs) previously associated with CRP. We employed weighted/penalized weighted–medians and MR gene–environment interactions that allow instruments’ invalidity to some extent and attenuate the heterogeneous estimates of outlying SNPs.

**Results:** In lifestyle-stratification analyses, genetically elevated CRP decreased risk for breast cancer in exogenous estrogen-only, estrogen + progestin, and past oral contraceptive (OC) users, but only among relatively short-term users (< 5 years). Estrogen-only users for ≥ 5 years had more profound CRP-decreased breast cancer risk in dose-response fashion, whereas past OC users for ≥ 5 years had CRP-increased cancer risk. Also, genetically predicted CRP was strongly associated with increased risk for hormone-receptor positive or human epidermal growth factor receptor-2 negative breast cancer.

**Conclusions:** Our findings may provide novel evidence on the immune-related pathways linking to breast cancer risk, and suggest potential clinical use of CRP to predict the specific cancer subtypes and CRP–inflammatory marker targeting interventions to reduce postmenopausal breast cancer risk.

Background

Invasive breast carcinoma in postmenopausal women ages 50 years and older accounts for the majority (approximately 80%) of new breast cancer cases and related deaths [1]. The probability of newly diagnosed patients at 50 years and older is twice as large as that of those younger than 50 (4.3% vs. 2.0%) [2], contributing to breast cancer ranking highest in cancer incidence in women of the United States and worldwide [2]. Chronic inflammation may be a critical factor in the pathogenesis of obesity-associated cancers, such as postmenopausal breast cancer, from tumor initiation to progression [3]. Adipose tissue increases macrophage infiltration that forms “crown-like structures” (CLSs) surrounding adipocytes, leading to a condition of chronic low-grade inflammation [4]. The innate immunity response elevates the circulating levels of cancer-promoting inflammatory cytokines, creating a tissue microenvironment high in reactive oxygen and nitrogen species, leading to potential DNA damage and alterations in nearby cells [5]. In particular, C-reactive protein (CRP) is a key pro-inflammatory biomarker, acting as a major acute-phase reactant and a biomarker of chronic low-grade inflammation, which has been implicated in carcinogenesis [3]. For example, CRP, together with inflammatory cells and mediators, creates a pro-neoplastic environment for tumor growth by inducing DNA damage and promoting angiogenesis [5]. Thus, circulating CRP levels reflect the magnitude of inflammation in the microenvironment that is favorable to tumor development and, particularly the levels measured at diagnosis, are associated with larger tumor size, lower tumor grade, and presence of metastasis [6].

For postmenopausal breast cancer, obesity is a well-established risk factor [7], and CLSs are frequently found in the breasts of obese women, the extent of which is correlated with adipocyte size, thus reflecting the severity of pro-tumorigenic inflammation in breasts [8]. Enhanced secretion of CRP in these obese conditions could be involved in breast cancer development and progression, but the molecular mechanisms are only partially understood. In detail, cyclooxygenase-2 (COX-2) levels increase in inflamed breast tissue of obese women and directly contribute to increased aromatase activity which plays a critical role in breast carcinogenesis and, in turn, stimulates proliferation of the tumorous breast epithelium [8]. CRP levels are reduced when COX-2 action is inhibited [9], suggesting that obesity-related aromatase activity in breast tumorigenesis correlates with inflammation. In addition to the local control of estrogen synthesis in breast tissue, the CRP-inflammatory marker can cause a systemic increase in circulating estrogen levels in obese women [10]. Previous observational and genetic epidemiologic studies, however, yielded conflicting findings for an association between circulating CRP and breast cancer, with mostly null results [11–13] and a few positive associations with weak or modest strength [14, 15].

A Mendelian randomization (MR) approach may provide better insight into the immune-related etiologic pathways connected to invasive breast cancer risk. MR evaluates the exposure (e.g., CRP) on an outcome (e.g., breast cancer risk) using genetic variants as an instrumental variable [16]. This approach may provide a relatively unbiased causal inference between CRP and breast cancer risk, because (i) MR can reduce potential confounding given random assignment of exposure owing to randomly assorted relevant genetic alleles at the time of gamete formation; the alleles are thus generally unrelated to environmental factors, and (ii) MR can address short-term exposures to inflammatory biomarkers by using the associated alleles as a proxy for lifelong exposure [16, 17]. MR may also reduce the possibility of reverse causation in that alleles precede the phenotype and relevant clinical outcomes [17]. Thus, in an MR framework, the elevated CRP concentrations are less likely to result from the immune response induced by premalignant or preclinical tumor growth. Finally, an MR study could be comparable to randomized clinical trials in providing a robust causal relationship if the genetic instruments are valid and not linked to cancer outcomes via alternative pathways other than those of the CRP phenotype [16].

In this study, we performed MR analysis by focusing on postmenopausal women who are vulnerable to a high incidence of inflammation [18], obesity, and breast cancer. In our earlier genome-wide association (GWA) meta-analysis of gene–environment (G-E) interaction study for CRP [19], we used data from the Database for Genotypes and Phenotypes (dbGaP) on a large-scale cohort of postmenopausal women in the Women’s Health Initiative (WHI). In addition to including the single-nucleotide polymorphisms (SNPs) identified in our previous GWA study [19], we have now extended the scope of modeled genetic instruments by adding GWA SNPs for CRP from previous GWA studies that targeted European ancestry with independent replications [20–22]. We employed recently developed MR analyses, including weighted median (WM) and penalized weighted median (PWM) estimates [23, 24] and MR G-E interactions [25] to allow some relaxation on the strict rules for MR instrumental variables, to down weight the contribution of heterogeneity of genetic variants to analysis, and to incorporate interactions between genes and obesity–/sex hormone– related lifestyles in the MR analysis. We tested the hypothesis that genetically determined CRP has a potentially causal association with invasive breast cancer risk.
Materials And Methods

Study population

We used data from the WHI dbGaP Harmonized and Imputed GWA Studies (GWASs) which were coordinated to contribute to a joint imputation and harmonization effort for GWASs. Those studies, under dbGaP study accession number (phs000200.v12.p3), consist of 5 GWASs (AS264, GARNET, GECCO, HIPFX, and WHIMS) (Table 1) and encompass the 2 WHI representative study arms, Clinical Trials and Observational Studies, representing one of the largest studies on postmenopausal women in the U.S. to date. The detailed study designs and rationale are described elsewhere [26]. Healthy women were enrolled in the WHI study between 1993 and 1998 at 40 clinical centers across the U.S if they were 50–79 years old, postmenopausal, expected to stay near the clinical centers for at least 3 years after enrollment, and able to provide written informed consent. Participants were further eligible for the WHI dbGaP study if they had met eligibility requirements for data submission to dbGaP and provided DNA samples. Of a total of 16,088 women who reported their race or ethnicity as non-Hispanic white, we applied exclusion criteria (history of diabetes, genomic data quality control, less than 1 year follow-up of cancer outcomes, and diagnosis of any cancer type at screening), resulting in a total of 10,170 women (Table 1 includes the number of participants in each study). They had been followed up through August 29, 2014, a mean of 16 years’ follow-up and 537 (5% of the eligible 10,170 women) developed primary invasive breast cancer. The studies were approved by the institutional review boards of each WHI clinical center and the University of California, Los Angeles.
Table 1
Genome-wide SNPs and their associations with CRP concentrations in previous GWASs

| SNP & Allele | Chr | Position | Gene | Ref | Alt | OR/beta | SE | p     |
|-------------|-----|----------|------|-----|-----|---------|----|-------|
| rs2794520   | 1   | 159678816| CRPP1/CRP | C   | T   | 1.216   | 0.031 | 1.60E-10 |
| rs2243458   | 12  | 121424490| HNF1A   | C   | T   | 1.244   | 0.031 | 2.26E-12 |
| rs1169311   | 12  | 121440731| C12orf43 | C   | T   | 1.190   | 0.030 | 5.64E-09 |
| rs429358    | 19  | 45411941 | APOE    | T   | C   | 1.319   | 0.045 | 8.30E-10 |
| rs5117      | 19  | 45418790 | APOC1   | T   | C   | 1.327   | 0.051 | 3.06E-08 |
| rs75460349  | 1   | 27180088 | ZDHHC18 | C   | A   | 0.086   | 0.014 | 4.50E-10 |
| rs2293476   | 1   | 40036847 | PABPC4  | G   | C   | 0.030   | 0.004 | 8.27E-13 |
| rs1805096   | 1   | 66102257 | LEPR    | A   | G   | 0.088   | 0.004 | 1.29E-12 |
| rs469772    | 1   | 91530305 | ZNF644  | T   | C   | 0.031   | 0.005 | 5.54E-12 |
| rs4129267   | 1   | 154426264| IL6R    | T   | C   | 0.088   | 0.004 | 1.29E-12 |
| rs2794520   | 1   | 159678816| CRPP1/CRP| T   | C   | 0.086   | 0.014 | 4.50E-10 |
| rs1800947   | 1   | 159683438| CRP     | G   | C   | 0.031   | 0.005 | 5.54E-12 |
| rs1417938   | 1   | 159684186| CRP     | T   | C   | 0.088   | 0.004 | 1.29E-12 |
| rs10925027  | 1   | 247612562| NLRP3   | C   | T   | 0.036   | 0.004 | 4.25E-21 |
| rs12995480  | 2   | 629881   | TMEM18  | T   | C   | 0.031   | 0.005 | 1.24E-10 |
| rs1260326   | 2   | 27730940 | GCKR    | C   | T   | 0.073   | 0.004 | 2.72E-09 |
| rs4246598   | 2   | 88438050 | FABP1   | C   | A   | 0.022   | 0.004 | 5.11E-10 |
| rs9284725   | 2   | 102744854| IL1R1   | A   | C   | 0.027   | 0.004 | 7.34E-10 |
| rs13409371  | 2   | 113838145| IL1F10  | G   | A   | 0.048   | 0.004 | 5.07E-36 |
| rs1441169   | 2   | 214033530| IKZF2   | G   | A   | 0.025   | 0.004 | 2.27E-11 |
| rs2352975   | 3   | 49891885 | TRAIP   | T   | C   | 0.025   | 0.004 | 6.43E-10 |
| rs1514895   | 3   | 170705693| EIF5A2  | A   | G   | 0.027   | 0.004 | 2.70E-09 |

GWASs analyzing CRP as a binary outcome reflecting high immune response and chronic inflammation (CRP > 3.0 mg/L)

GWASs analyzing CRP as a continuous variable that was naturally log-transformed (mg/L)
| SNP & | Chr | Position | Gene       | Ref | Alt | Alt allele frequency | OR/beta | SE |
|-------|-----|----------|------------|-----|-----|----------------------|---------|----|
| rs4705952 | 5 | 131839618 | IRF1 | A | G | 0.25 | NA | 0.26 |
| rs17658229 | 5 | 172191052 | DUSP1 | T | C | 0.04 | NA | 0.04 |
| rs9271608 | 6 | 32591588 | HLA-DQA1 | A | G | 0.17 | NA | 0.17 |
| rs12202641 | 6 | 116314634 | FRK | T | C | 0.59 | NA | 0.59 |
| rs6901250 | 6 | 117114025 | GPRC6A | G | A | 0.33 | NA | 0.33 |
| rs1490384 | 6 | 126851463 | CENPW | T | C | 0.49 | NA | 0.49 |
| rs9385532 | 6 | 130371227 | L3MBTL3 | T | C | 0.67 | NA | 0.67 |
| rs1880241 | 7 | 22759469 | IL6 | G | A | 0.52 | NA | 0.52 |
| rs2710804 | 7 | 36084529 | EEPD1 | T | C | 0.37 | NA | 0.37 |
| rs13233571 | 7 | 72971231 | BCL7B | T | C | 0.89 | NA | 0.89 |
| rs4841132 | 8 | 9183596 | PPP1R3B | A | G | 0.91 | NA | 0.91 |
| rs2064009 | 8 | 117007850 | TRPS1 | C | T | 0.58 | NA | 0.58 |
| rs2891677 | 8 | 126344208 | NSMCE2 | C | T | 0.55 | NA | 0.55 |
| rs643434 | 9 | 136142355 | ABO | G | A | 0.36 | NA | 0.36 |
| rs1051338 | 10 | 91007360 | LIPA | T | G | 0.30 | NA | 0.30 |
| rs10832027 | 11 | 13357183 | ARNTL | G | A | 0.68 | NA | 0.68 |
| rs10838687 | 11 | 47312892 | MADD | G | T | 0.79 | NA | 0.79 |
| rs1582763 | 11 | 60021948 | MS4A4A | A | G | 0.64 | NA | 0.64 |
| rs7121935 | 11 | 72496148 | STARD10 | A | G | 0.66 | NA | 0.66 |
| rs11108056 | 12 | 95855385 | METAP2 | G | C | 0.56 | NA | 0.56 |
| rs10778215 | 12 | 103537266 | C12orf42 | A | T | 0.53 | NA | 0.53 |
| rs7310409 | 12 | 121424861 | HNF1A | A | G | 0.62 | NA | 0.62 |
| rs2239222 | 14 | 73011885 | RGS6 | A | G | 0.36 | NA | 0.36 |
| rs112635299 | 14 | 94838142 | SERPINA1/SERPINA2P | T | G | 0.98 | NA | 0.98 |

Cont. GWASs analyzing CRP as a continuous variable that was naturally log-transformed (mg/L)
Participants’ demographic and lifestyle factors were collected at screening by self-administered questionnaires, and the collection process was monitored periodically for data quality assurance by the coordinating clinical centers. With 48 initially selected variables derived from literature review for their association with inflammation and breast cancer [27–29], we performed preliminary analyses including univariate and stepwise multiple regression analyses and a multicollinearity test and finally selected the following 15 variables for analysis: demographic and socioeconomic factors (age, education, and family income); a family history of breast cancer and depressive symptoms; lifestyle factors (cigarette smoking and physical activity); dietary factors (daily alcohol and saturated fatty acids [SFA] intake); and reproductive history (age at menopause, durations of oral contraceptive [OC] use and of exogenous estrogen [E]–only and E plus progestin [E + P] use). Also, anthropometric variables (height, weight, and waist/hip circumferences) that had been measured by trained staff were included. For stratification analyses, we used the following cutoff values: 30 kg/m² body mass index (BMI), 0.85 waist-to-hip ratio (WHR), 10 hours/week metabolic equivalent (MET), and 9% calories from SFA on the basis of obesity and related lifestyle guidelines [30–32]; 0.06 on the depressive scale of the Center for Epidemiological Studies [33]; 15 cigarettes smoked daily; 14 g (one drink for women) of alcohol intake daily [34]; a 5-year interval of E-only/E + P use ranging from nonuse to 15 years or longer; and a 5-year median of OC use.

Primary invasive breast cancer diagnosis as our outcome of interest was determined via a centralized review of medical charts and pathology and cytology reports by a committee of physicians. Cancer cases were coded using the National Cancer Institute’s Surveillance, Epidemiology, and End-Results guidelines [35]. The time from enrollment to breast cancer development, censoring, or study end point was calculated and presented in years.

Genotyping And Instrumental Variables

Genotyped data was extracted for this study from the WHI dbGaP Harmonized and Imputed GWASs. Details of genotyping and imputation and the data-cleaning process have been reported [19, 26, 36]. In brief, DNA was obtained from blood samples and genotyped using several GWAS platforms [26]. The genotypes were normalized to Genome Reference Consortium Human Build 37, and genomic imputation was performed via the 1000 Genomes reference panels [37]. SNPs were checked for harmonization with pairwise concordance among all samples across the GWASs. Through the initial and second data quality–control steps, SNPs were included by filtering on a missing-call rate of < 2%, a Hardy-Weinberg equilibrium of p ≥ 1E–04, and $R^2 \geq 0.6$ imputation quality [38], but individuals with unexpected duplicates, first- and second-degree relatives, and outliers on the basis of principal components (PCs) were excluded.

We used 4 GWAS resources to select CRP-SNPs: one from our earlier GWAS using the WHI Harmonized and Imputed GWASs that examined CRP as a binary outcome, reflecting chronic low-grade inflammation status with > 3.0 mg/L of CRP [39, 40]. Using the same population of genetic instruments and cancer outcomes may reduce bias from the MR analysis of different population structures between exposure and outcome. Of 82 SNPs in total, we selected 5 index/independent SNPs that were not in linkage disequilibrium (i.e., LD < 0.3) (Table 1). The other 3 GWASs recently reported CRP SNPs analyzing CRP as a continuous variable that was naturally log-transformed (mg/L). They used different genotype and analytic strategies, such as HapMap-based 1000 Genomes imputed data analysis [20], genome-wide discovery analysis and replication panel [22], and genome-wide common and low/rare coding variants search [21]. Of the total 89 SNPs from the 3 studies, 16 SNPs overlap; the analysis results from the more recent study were selected. With LD < 0.3, 61 independent SNPs (the 5 from our study plus 56 from other studies) were finally included in our analysis (Table 1). The allele associated with higher CRP level was assigned to an alternative (risk) allele, whereas the other as a reference allele for all SNPs.

Statistical analysis

Three basic assumptions are necessary for a genetic variant to be valid in MR analysis: (i) the variant is robustly predictive of the exposure; (ii) the variant is independent of factors that confound the exposure–outcome association; and (iii) the variant is independent of the outcome, given the exposure and confounding factors of the exposure–outcome association (i.e., the variant has no pleiotropic pathways other than the exposure) [41]. We checked whether our data met the assumptions for a valid inference. The first assumption was addressed by selecting only SNPs that were associated with CRP at genome-wide significance. The inter-individual variability of CRP explained by all of the selected SNPs was about 6% [21, 22, 23]. The WM estimate allows up to 50% of genetic variants’ invalidity (i.e., the assumptions violated) and provides a more consistent

We conducted the MR analysis separately according to the CRP variable type analyzed in the GWASs: binary chronic inflammation status or continuous levels. In addition to a traditional inverse-variance weighed (IVW) method [46], we employed recently developed MR approaches such as WM/PWM estimates [23, 24] and MR G–E interactions [25]. The WM estimate allows up to 50% of genetic variants’ invalidity (i.e., the assumptions violated) and provides a more consistent estimate of the causal effect if the precision of the individual estimates varies considerably, by assigning a weight to the ordered estimate and establishing linearity between neighboring estimates [24]. When the estimates from invalid instruments are not balanced about the true effect, the WM, however, is inappropriate; the PWM estimate can minimize this issue by down-weighting outlying genetic variants with heterogeneous estimates [24]. The PWMs may also be a better parameter if there is directional pleiotropy. In each MR analysis, we performed exploratory stratified analyses defined by potential effect modifiers, including lifestyle factors and breast cancer molecular subtypes. Further, we calculated a corrected MR estimate by taking into account the interaction of genes with selected obesity-related factors (BMI, WHR, MET, % calories from SFA, alcohol, and depressive symptoms) and sex hormone–lifestyles (E-only, E + P;
and OC use) by applying the MR G-E method [25]. We created a weighted genetic score (GS) for that analysis using a polygenic additive model [47] with the 56 CRP-SNPs from previous GWASs that analyzed CRP as a continuous variable. We then rescaled the GS to the unit of CRP by performing a linear regression among women without breast cancer; by using β0 (slope) and β1 (intercept), we computed the scaled CRP-GS (= β0 + β1-GS), where 2 GSs were perfectly corrected (r = 1.0) [23, 47].

In the MR analysis for the 5 SNPs from our earlier GWAS, we adjusted a correlation between CRP phenotype and breast cancer in which exposure and outcome were evaluated within the same population. For parameters necessary for the MR analysis, the change in CRP (> 3.0 vs. ≤ 3.0 mg/L) in log-odds and the mean change in log-transformed CRP per allele were obtained from our and the 3 other previous GWASs, respectively. The effect of genetic variants on breast cancer risk was calculated in our study population by using Cox regression with adjustment for (i) age and 10 PCs and (ii) lifestyle covariates in addition to age and 10 PCs. The assumption test was conducted via a Schoenfeld residual plot and p evaluation. The Cox results from each of our 5 GWASs were combined using fixed-effect meta-analysis. The final MR results were reported as risk ratios (particularly, hazard ratios [HRs]) and 95% confidence intervals (CIs) for the change in breast cancer risk per unit increase in log-odds or log-transformed CRP.

The heterogeneity of the MR estimate, reflecting additional evidence of pleiotropy, was estimated using Cochran's Q test. A 2-tailed p < 0.05 was considered statistically significant. R3.6.3 (survival, metaphor, forestplot, ggplot2, and ggthemes packages) was used.

**Results**

The total of 61 GWA SNPs identified for their association with CRP concentrations are presented in Table 1; 5 were from our GWAS analyzing binary CRP outcomes (> 3.0 mg/L vs. ≤ 3.0 mg/L, reflecting low-grade chronic inflammation status), and the other 56 from 3 other previous GWASs examining continuous natural log-transformed CRP (mg/L). The association between each of the 61 SNPs and breast cancer risk are shown in Additional file 1: Table S2, including results from the first stage of adjustment for age and 10 PCs and from the second stage of adjustment for lifestyle covariates in addition to age and 10 PCs. The pooled analysis for the genetic instruments combining 5 SNPs (Fig. 1A) and 56 SNPs (Fig. 1B) each did not reveal statistically significant associations (the 5 SNPs’ PWM-HR\textsubscript{2nd stage} = 0.78, 95% CI: 0.52−1.16; the 56 SNPs’ PWM-HR\textsubscript{2nd stage} = 0.91, 95% CI: 0.56−1.49). Removing pleiotropic SNPs did not apparently change the pooled estimates.

We performed stratification analysis defined by obesity-related factors, lifestyles, a family history of breast cancer, depressive symptoms, and exogenous estrogen use. In the MR analysis of our 5 CRP-SNPs, a 1-unit increase in the genetically predicted chronic inflammation (defined as > 3.0 mg/L of CRP) was associated with approximately 80% decreased risk of breast cancer among E + P users, particularly in women with < 5 years’ use of E + P (PWM-HR\textsubscript{1st stage} = 0.17, 95% CI: 0.05−0.63) (Table 2). The reduced effect on breast cancer risk was more profound in stage 2 of the MR analysis, which used the SNP–cancer association adjusted for lifestyles in addition to age and 10 PCs. Likewise, genetically determined chronic inflammation status was associated with reduced risk for breast cancer among E-only users. In particular, the cancer risk was reduced by 50% in E-only users for < 5 years and more substantially decreased in longer-term users, showing a dose-response relationship (Fig. 2). Of note, this reduced risk of cancer in E-only users was present only in the first MR stage. The MR-Egger test showed no significant evidence of directional pleiotropy across the tested associations (Table 2 and Fig. 2).
Table 2
Mendelian randomization analysis: the effect of generically predicted chronic inflammation status on breast cancer risk by exogenous estrogen plus progestin use

| GWAS examining CRP as a binary outcome reflecting high immune response and chronic inflammation (CRP > 3.0 mg/L) | Stage 1 |  | Stage 2 |  |
|---|---|---|---|---|
| | | Adjustment for age and 10 PCs | Stage 2 | Adjustment for covariates* in addition to age and 10 PCs |
| | |  |  |
| Analytic method | HR\(\hat{\beta}\) (95% CI) | p | p-het† | HR\(\hat{\beta}\) (95% CI) | p | p-het† |
|---|---|---|---|---|---|---|
| < Exogenous estrogen plus progestin nonusers > | | | | | | |
| Inverse-variance weighted | 1.02 (0.69 - 1.50) | 0.892 | 0.652 | 0.95 (0.65 - 1.40) | 0.735 | 0.656 |
| Weighted median | 0.96 (0.62 - 1.49) | 0.860 | 0.93 (0.60 - 1.44) | 0.753 | |
| Penalized weighted median | 0.96 (0.63 - 1.46) | 0.854 | 0.93 (0.60 - 1.45) | 0.756 | |
| MR-Egger: slope | 2.98 (0.38 - 23.60) | 0.192 | 2.82 (0.36 - 21.83) | 0.206 | |
| intercept | 0.79 (0.50 - 1.24) | 0.193 | 0.79 (0.50 - 1.23) | 0.185 | |
| < Exogenous estrogen plus progestin use < 5 years > | | | | | | |
| Inverse-variance weighted | 0.27 (0.04 - 1.65) | 0.115 | 0.110 | 0.00 (0.00 - 2.76E + 17) | 0.305 | < 0.005 |
| Weighted median | 0.19 (0.05 - 0.69) | 0.011 | 0.03 (0.003 - 0.20) | < 0.005 | |
| Penalized weighted median | 0.17 (0.05 - 0.63) | 0.007 | 0.02 (0.00 - 1.02) | 0.051 | |
| MR-Egger: slope | 0.05 (0.00 - 18942.43) | 0.512 | 0.00 (0.00 - 1.05E + 87) | 0.205 | |
| intercept | 1.46 (0.09 - 24.79) | 0.700 | 1.13E + 17 (0.00 - 4.09E + 55) | 0.254 | |

CI, confidence interval; CRP, C-reactive protein; GWAS, genome-wide association study; HR, hazard ratio; MR, Mendelian randomization; PCs, principal components; SFA, saturated fatty acids; SNP, single-nucleotide polymorphism. Numbers in bold face are statistically significant.

* Covariates adjusted in the analyses for the association between genome-wide SNPs and breast cancer risk include education; annual family income; family history of breast cancer; body mass index; waist-to-hip ratio; physical activity; depressive symptoms; number of cigarettes per day; dietary alcohol in g/day; % calories from SFA/day; age at menopause; duration of oral contraceptive use; and duration of exogenous estrogen–only use.

† The Mendelian randomization estimate (except weighted/penalized weighted medians) was adjusted for a correlation between CRP phenotype and breast cancer risk within the same population.

‡ Heterogeneity in estimates among genome-wide SNPs was evaluated with Cochran's Q test with fixed effects.

Similarly, in the MR analysis of the other 56 SNPs, a 1-unit increase in the log-transformed genetically elevated CRP was associated with about 20% reduced risk for breast cancer among women who had used OC for < 5 years (Fig. 3); the estimates remained consistent in the second stage of MR analysis after excluding pleiotropic SNPs. However, a different pattern was observed among longer-term past OC users. Genetically elevated CRP levels were strongly associated with increased breast cancer risk in past OC users for ≥ 5 year (IVW-HR\(2^{nd}\) - stage = 2.14, 95% CI: 1.11–4.10, after exclusion of pleiotropic SNPs). No directional pleiotropy was observed.

In addition, we stratified breast cancer patients by molecular subtype (estrogen and progesterone receptor [ER/PR] and human epidermal growth factor receptor 2 [HER2/neu] status). A 1-unit increase in the log-transformed genetically elevated CRP level was associated with 80% or more increased risk for ER/PR-positive breast cancer (IVW-HR\(1^{st}\) - stage = 1.79, 95% CI: 1.17–2.76; WM-HR\(1^{st}\) - stage = 2.11, 95% CI: 1.00–4.46) (Table 3). The IVW estimate in the first stage remained statistically significant after exclusion of pleiotropic SNPs (Table 3), with no evidence of heterogeneous and directional pleiotropic effects of the SNPs. Of note, a stronger increased risk of breast cancer was observed for the genetic instruments of CRP in HER2/neu-negative breast cancer. For example, women with genetically elevated CRP were 3 times more likely to develop HER2/neu-negative breast cancer (PWM-HR\(2^{nd}\) - stage = 3.20, 95% CI: 1.27–8.08, after exclusion of pleiotropic SNPs) (Table 3). No other subgroups revealed a statistically significant association between genetically determined chronic inflammation or CRP levels and breast cancer risk (Additional file 1: Tables S3 and S4).
Table 3
Mendelian randomization analysis: the effect of genetically predicted CRP phenotype on breast cancer risk by ER/PR a

GWASs analyzing CRP as a continuous variable that was naturally log-transformed (mg/L)

| Analytic method | All SNPs | | | | After exclusion of pleiotropic SNPs | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | Stage 1 | Stage 2 | Stage 1 | Stage 1 | | | |
| Adjustment for age and 10 PCs | Adjustment for covariates* in addition to age and 10 PCs | Adjustment for age and 10 PCs | | | | |
| HR (95% CI) | p | p* | HR (95% CI) | p | p* | HR (95% CI) | p |
| --- | --- | --- | --- | --- | --- | --- | --- |
| < ER/PR positive > | | | | | | | |
| Inverse-variance weighted | 1.79 (1.17 - 2.76) | 0.009 | 0.209 | 1.81 (0.97 - 3.39) | 0.064 | < 0.005 | 1.80 (1.11 - 2.93) | 0.018 |
| Weighted median | 1.72 (0.97 - 3.07) | 0.065 | 2.11 (1.00 - 4.46) | 0.049 | 1.85 (0.99 - 3.47) | 0.055 |
| Penalized weighted median | 1.77 (0.98 - 3.17) | 0.057 | 2.10 (1.00 - 4.40) | 0.050 | 1.89 (0.98 - 3.64) | 0.056 |
| MR-Egger: slope | 1.94 (1.02 - 3.69) | 0.042 | 2.30 (0.91 - 5.81) | 0.078 | 1.98 (0.96 - 4.10) | 0.065 |
| intercept | 0.99 (0.96 - 1.03) | 0.731 | 0.98 (0.93 - 1.04) | 0.484 | 0.99 (0.95 - 1.04) | 0.730 |
| < HER2/neu negative > | | | | | | | |
| Inverse-variance weighted | 1.89 (1.15 - 3.10) | 0.013 | 0.187 | 1.83 (0.91 - 3.67) | 0.089 | 0.006 | 2.09 (1.21 - 3.46) | 0.010 |
| Weighted median | 2.07 (1.02 - 4.17) | 0.043 | 2.10 (0.87 - 5.08) | 0.099 | 2.80 (1.34 - 5.87) | 0.006 |
| Penalized weighted median | 2.13 (1.11 - 4.11) | 0.024 | 2.01 (0.83 - 4.85) | 0.121 | 3.00 (1.48 - 6.08) | 0.002 |
| MR-Egger: slope | 2.60 (1.25 - 5.41) | 0.011 | 2.08 (0.74 - 5.89) | 0.163 | 3.19 (1.41 - 7.23) | 0.006 |
| intercept | 0.98 (0.93 - 1.02) | 0.240 | 0.99 (0.93 - 1.05) | 0.732 | 0.97 (0.93 - 1.01) | 0.172 |

CI, confidence interval; CRP, C-reactive protein; ER/PR, estrogen and progesterone receptor; GWAS, genome-wide association study; HER2/neu, human epidermal principal components; SFA, saturated fatty acids; SNP, single-nucleotide polymorphism. Numbers in bold face are statistically significant.

* Covariates adjusted in the analyses for the association between genome-wide SNPs and breast cancer risk include education; annual family income; family ratio; physical activity; depressive symptoms; number of cigarettes per day; dietary alcohol in g/day; % calories from SFA/day; age at menopause; duration of estrogen [E]–only use and E plus progestin use.

† Heterogeneity in estimates among genome-wide SNPs was evaluated with Cochran's Q test with fixed effects.

B. Fifty-six genome-wide SNPs associated with CRP phenotype that was naturally log-transformed (mg/L) (PWM HR*2nd - stage = 0.91, 95% CI: 0.56–1.49; MR-

Discussion

We further performed MR G-E analyses to estimate the corrected MR estimates by incorporating the G-E interactions with the selected obesity and sex-hormone lifestyle factors; none of the estimates reached statistical significance and no pleiotropic effect of the estimates was detected (Additional file 1: Table S5).

We performed MR analyses for genetically predicted CRP levels (>3 mg/L vs. ≤ 3.0 mg/L, indicating chronic low-grade inflammation or a natural log-transformed 1 mg/L increase) in association with postmenopausal breast cancer risk and showed that genetically elevated CRP levels increased the risk for breast cancer in women with particular lifestyle factors and breast cancer subtypes. MR findings, if the modeled genetic instruments are not linked to the outcome via any alternative pathway and are not associated with confounders of the exposure–outcome association, may be comparable with those of randomized clinical trials [46], thus providing a robust causal inference. Our MR analysis reduced the pleiotropic effect by identifying a wide range of confounding factors that are connected to the CRP–breast cancer pathway and accounting for them in the analysis of the genetic instrument–cancer outcome association, and by removing the pleiotropic SNPs that may confound the association between CRP and breast cancer. Our MR estimates, including WM and PWM, allow some relaxation of the restrictions on instrumental variables, and thus provide a more robust estimate of the causal effect than a
traditional MR estimate. To our knowledge, this study is the first to report the causal effect of genetically elevated CRP levels on increased breast cancer risk in an MR framework.

Most previous epidemiological studies examining the measured CRP levels showed no significant association with breast cancer risk [11–13], despite the potential role of CRP in breast cancer carcinogenesis both systemically and locally. As pointed out in the previous studies, reverse causation could not be ruled out. For example, the chronic inflammatory status with elevated CRP levels may be involved in cancer cell initiation and growth [13, 48], but it may also be the consequence of tumor progression, as shown by the infiltration of CD4+ and CD8+ regulatory T lymphocytes in breast cancer tissues that is associated with poor cancer survival [49]. Thus, several studies have showed the effect of high CRP levels as leading to a worse prognosis after the diagnosis of breast cancer [6, 13]. In addition, CRP levels are easily influenced by various modifiable and non-modifiable factors such as physiologic and pathologic stimuli, reflecting the inconclusiveness of one or a few time measurements.

An MR study is not likely to be susceptible to reverse causation and potential confounding owing to a random assortment of the genetic alleles at the time of gamete formation before the disease onset. Further, MR can allow the assessment of a long-standing effect of CRP on cancer development. Until now, we have found only one published MR study on the CRP phenotype and breast cancer risk [50]. That study used 4 SNPs in the CRP gene with 9 genotype combinations and adjusted for lifestyle confounding; no significant association was reported. Our study utilized 61 CRP-associated SNPs from the most recently updated GWASs and, with no evidence of violation for weak genetic instruments and directional pleiotropy, we conducted MR analyses with 2 separate stages of lifestyle adjustments.

We further conducted stratification analyses by obesity, sex-hormone and breast cancer subtype to determine whether these lifestyle and pathologic factors modified the association between genetically elevated CRP and breast cancer risk. We detected a substantially reduced risk of breast cancer in relation to CRP in E-only, E + P and past OC users, but only among relatively short-term users (< 5 years). In particular, longer-term E-only users (≥ 5 years) had more profound CPR-decreased cancer risk, in dose-response fashion. This finding is not align with our other finding of CRP-increased ER/PR-positive breast cancer risk. It may reflect the different effect of estrogen on cancer risk when it is taken orally, and our finding is supported by previous studies [51, 52] showing that oral intake of estrogen, due to its first-pass metabolic effect of suppressing hepatic production of IGF-I, reduced insulin-like growth factor-I (IGF-I), a carcinogenic promoter which it is partly induced by CRP, thus suggesting the protective role of exogenous estrogen in postmenopausal breast cancer risk [53].

In contrast, E + P users have different levels of IGF-I and cancer risk owing to non–progesterone-like effects (i.e., different effects from natural progesterone), contrasting with the hepatocellular effect of oral estrogen [54]; but, the mechanism is not completely clear. In addition, synthetic progestin has an affinity for androgen and mineralocorticoid receptors, leading to cell proliferation and anti-apoptosis, contributing to breast carcinogenesis [55]. In our MR study, only longer-term users of E + P (≥ 5 years) had CRP-increased risk for breast cancer, implying an effect of long-term cumulative exposure to synthetic progestin, although this association did not reach statistical significance; that result warrants future studies with a larger population for more definitive results. Similarly, the women in our study who had used OC for ≥ 5 years in the past had a strongly CRP-increased risk for breast cancer. This result is consistent with previously published findings from other studies [56, 57] that showed increased breast cancer risk with long-term duration of OC use. The use of OC, especially those containing E + P, increases the proliferation of human breast epithelial cells [55], which may partially support our findings of increased cancer risk in long-term OC and E + P users. Our data sources had no information about the type of OC preparation our participants had taken; this calls for a future study that examines the potentially different effects on cancer risk according to specific OC formulations.

In addition, genetically elevated CRP in our study was strongly associated with increased risk for ER/PR-positive breast cancer, which is consistent with recent findings [58], suggesting a role of inflammation in obesity-induced hormone receptor–positive breast cancer development. Excessive adiposity characterized by adipocyte hypertrophy leads to chronic inflammation of adipose tissues, forming CLSs; the inflamed breast CLSs in turn produce inflammatory molecules such as CRP and other cytokines, leading to the activation of nuclear factor-kB that elevates aromatase production, thus logically driving hormone receptor–positive tumor growth [58]. We also found that genetically predicted CRP was associated with increased risk of HER2/neu-negative breast cancer. In accord with the results of a few previous studies [48, 59], our finding supports a potential mechanism connecting inflammation to HER2/neu-negative breast cancer, in which pro-inflammatory markers trigger JAK/STAT signaling pathways, activating genes responsible for cell proliferation and angiogenesis, and those aberrant pathways then contribute to an immunosuppressive tumorigenic microenvironment, leading to more aggressive breast cancer such as basal-like tumors [13, 48, 59].

We performed a diagnostic test for MR directional pleiotropy and reduced any problematic pleiotropic effect by applying several statistical methods: removal of pleiotropic SNPs, adjustment for confounding, incorporation of the gene–lifestyle interactions (MR G–E tests and stratification), and use of WM/PWM estimates. Nevertheless, we cannot completely rule out residual and unmeasured confounding that might have affected our study findings. In addition, potential violation of a linearity assumption in the SNP–exposure and exposure–outcome analyses would result toward a null, rather than generating a spurious association [60]. Our study could lead to false-positive results due to multiple comparisons. Lastly, our study may not be generalized to other races or ethnicity, in which the relationship between genetic instruments, CRP, and breast cancer risk may be different.

Conclusions

Although our MR study was not designed to discover biologic mechanisms, our findings suggest a potential causal relationship between genetically elevated CRP levels and risk of postmenopausal breast cancer, particularly in relatively short-term users of exogenous estrogen. Also, lifetime exposure to elevated CRP levels is likely to influence the development of hormone receptor–positive and HER2/neu-negative breast cancer. Further biologic mechanistic study may help to elaborate the sex-hormone interactions with CRP on breast cancer carcinogenesis and the molecular pathways connected to CRP and ER/PR/HER2 receptors. Our findings may provide important novel evidence on immune-related etiologic pathways that influence breast cancer risk, and suggest the
potential clinical use of CRP to predict specific cancer subtypes and CRP—inflammatory marker-targeting interventions to reduce breast cancer risk in postmenopausal women.

Declarations

Ethics approval and consent to participate

The Institutional Review Boards of each WHI participating clinical center and the University of California, Los Angeles, approved this study. Participants provided written informed consent at enrollment.

Consent for publication

Not applicable

Availability of data and materials

The Women's Health Initiative Study data can be accessed via public repository (phs000200.v11.p3), which has been provided by authorized access (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v11.p3#restricted-access-section).

Competing interests

All authors declare no potential conflict of interest.

Funding

This study was supported by the National Institute of Nursing Research of the National Institutes of Health under Award Number K01NR017852 and a University of California Cancer Research Coordinating Committee grant (CRN-18-522722).

Authors' contributions

SYJ, JP, ES, MP, HY and ZZ designed the study. SYJ performed the genomic data QC and the statistical analysis and interpreted the data. JP and ES supervised the genomic data QC and analysis. MP HY participated in the study coordination and interpreting the data. SYJ secured funding for this project. ZZ supervised the project. All participated in the paper writing and editing. All authors have read and approved the submission of the manuscript.

Acknowledgements

Part of the data for this project was provided by the WHI program, which is funded by the National Heart, Lung, and Blood Institute, the National Institutes of Health, and the U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP accession (phs000200.v11.p3).

Program Office: National Heart, Lung, and Blood Institute, Bethesda, MD: Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy Geller.

Clinical Coordinating Center: Fred Hutchinson Cancer Research Center, Seattle, WA: Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg.

Investigators and Academic Centers: JoAnn E. Manson, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Barbara V. Howard, MedStar Health Research Institute/Howard University, Washington, DC; Marcia L. Stefanick, Stanford Prevention Research Center, Stanford, CA; Rebecca Jackson, The Ohio State University, Columbus, OH; Cynthia A. Thomson, University of Arizona, Tucson/Phoenix, AZ; Jean Wactawski-Wende, University at Buffalo, Buffalo, NY; Marian Limacher, University of Florida, Gainesville/Jacksonville, FL; Robert Wallace, University of Iowa, Iowa City/Davenport, IA; Lewis Kuller, University of Pittsburgh, Pittsburgh, PA; and Sally Shumaker, Wake Forest University School of Medicine, Winston-Salem, NC.

References

1. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017: https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf.

2. American Cancer Society. Cancer Fact and Figures, 2020. Atlanta: American Cancer Society, Inc.: https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf.

3. Disis ML. Immune regulation of cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(29):4531-4538.

4. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. Journal of lipid research. 2008;49(7):1562-1568.

5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
6. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. *Breast cancer research*. BCR. 2011;13(3):R55.

7. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nature reviews Cancer*. 2004;4(8):579-591.

8. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. *Cancer discovery*. 2012;2(4):356-365.

9. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. *Circulation*. 2004;110(8):934-939.

10. Nimptsch K, Pisched T. Obesity Biomarkers, Metabolism and Risk of Cancer: An Epidemiological Perspective. *Recent results in cancer research Fortschrritte der Krebsforschung Progres dans les recherches sur le cancer*. 2016;208:199-217.

11. Tibau A, Ennis M, Goodwin RJ. Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. *Breast cancer research and treatment*. 2013;141(3):485-493.

12. Ge I, Rudolph A, Shivanna P, Flesch-Jansy D, Hebert JR, Chang-Claude J. Dietary inflammation potential and postmenopausal breast cancer risk in a German case-control study. *Breast*. 2015;24(4):491-496.

13. Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, et al. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. *Carcinogenesis*. 2015;36(10):1121-1128.

14. Chan DS, Bandera EV, Greenwood DC, Norat T. Circulating C-Reactive Protein and Breast Cancer Risk-Systematic Literature Review and Meta-analysis of Prospective Cohort Studies. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2015;24(10):1439-1449.

15. Prizmets AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K, Joshu CE, et al. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. *Cancer causes & control: CCC*. 2013;24(12):2077-2087.

16. Shu X, Wu L, Khankari NK, Shu XO, Wang TJ, Michaillidou K, et al. Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. *Int J Epidemiol*. 2018.

17. Merino J, Leong A, Posner DC, Pomeala B, Masana L, Dupuis J, et al. Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. *Diabetes Care*. 2017;40(5):687-693.

18. Ellis J, Lange EM, Li J, Dupuis J, Baumert J, Walston JD, et al. Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. *Human genetics*. 2014;133(8):985-995.

19. Jung SY, Scott P, Papp J, Sobel E, Pellegrini M, Yu H, et al. Genome-wide association analysis of pro-inflammatory cytokines and gene–lifestyle interaction for invasive breast cancer risk: the WHI dbGaP Study. Submitted and Reviewed for publication. 2020.

20. Ligthart S, Vaez A, Vosa U, Stathopoulou MG, de Vries PS, Prins BP, et al. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. *American journal of human genetics*. 2018;103(5):691-706.

21. Schick UM, Auer PL, Bis JC, Lin H, Wei P, Pankratz N, et al. Association of exome sequences with plasma C-reactive protein levels in >9000 participants. *Human molecular genetics*. 2015;24(2):559-571.

22. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for reactive protein levels. *Circulation*. 2011;123(7):731-738.

23. Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, et al. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*. 2019;111(4):350-364.

24. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*. 2016;40(4):304-314.

25. Spiller W, Slichter D, Bowden J, Davey Smith G. Detecting and correcting for bias in Mendelian randomization analyses using Gene-by-Environment interactions. *Int J Epidemiol*. 2019;48(3):702-712.

26. NCBI: WHI Harmonized and Imputed GWAS Data. A sub-study of Women's Health Initiative. 2019. https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000746.v3.p3.

27. Orchard TS, Andridge RR, Yee LD, Lustberg MB. Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. *Journal of the Academy of Nutrition and Dietetics*. 2018;118(4):578-588 e571.

28. Simone V, D'Avenia M, Argentiero A, Felici C, Rizzo FM, De Pergola G, et al. Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. *The oncologist*. 2016;21(4):404-417.

29. Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, et al. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. *Journal of the National Cancer Institute*. 2015;107(9).

30. Center for Disease Control and Prevention. Overweight and Obesity. *Defining Adult Overweight and Obesity https://www.cdc.gov/obesity/adult/defining.html.*
33. Women's Health Initiative.Shortened CES-D/DIS screening instrument. Form 37 - Thoughts and Feelings 2001; https://sph.unc.edu/files/2013/07/form37.pdf.

34. 2015 – 2020 Dietary Guidelines for Americans. 2015;8th Edition. http://health.gov/sites/default/files/2019-09/2015-2020_Dietary_Guidelines.pdf.

35. National Cancer Institute. SEER Program: Comparative Staging Guide For Cancer. June 1993: https://seer.cancer.gov/archive/manuals/historic/comp_stage1.1.pdf.

36. Jung SY, Mancuso N, Yu H, Papp J, Sobel E, Zhang ZF. Genome-Wide Meta-analysis of Gene-Environmental Interaction for Insulin Resistance Phenotypes and Breast Cancer Risk in Postmenopausal Women. Cancer Prev Res (Phila). 2019;12(1):31-42.

37. NCBI: WHI Harmonized and Imputed GWAS Data. A sub-study of Women's Health Initiative: http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000746.v1.p3.

38. Schumacher FR, Al Olama AA, Benndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50(7):928-936.

39. Tao Q, Ang TFA, DeCarli C, Auerbach SH, Devine S, Stein TD, et al. Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers. JAMA network open. 2018;1(6):e183597.

40. Buckley DJ, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Annals of internal medicine. 2009;151(7):483-495.

41. VanderWeele TJ, Tchetgen Tchetgen EJ, Corneliis M, Kraft P. Methodological challenges in mendelian randomization. Epidemiology. 2014;25(3):427-435.

42. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755-764.

43. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740-752.

44. Carreras-Torres R, Johansson M, Gaborieau V, Haycock PC, Wade KH, Relton CL, et al. The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study. Journal of the National Cancer Institute. 2017;109(9).

45. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-525.

46. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-665.

47. Guo Y, Warren Anderssen S, Shu XO, Michailidou K, Bolla MK, Wang Q, et al. Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS medicine. 2016;13(8):e1002105.

48. Hong T, Liu A, Cai D, Zhang Y, Hua D, Hang X, et al. Preoperative serum C-reactive protein levels and early breast cancer by BMI and menopausal status. Cancer investigation. 2013;31(4):279-285.

49. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2014;25(8):1536-1543.

50. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-reactive protein and the risk of cancer: a mendelian randomization study. Journal of the National Cancer Institute. 2010;102(3):202-206.

51. Yu Z, Gao W, Jiang E, Lu F, Zhang L, Shi Z, et al. Interaction between IGF-IR and ER induced by E2 and IGF-I. PloS one. 2013;8(5):e62642.

52. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiate I, Kim HT, et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast cancer research and treatment. 2012;132(1):61-73.

53. Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From Women's Health Initiative Randomized Clinical Trials. JAMA oncology. 2015;3(3):299-305.

54. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Jama. 2004;291(14):1701-1712.

55. Cogliano V, Grosse Y, Baan R, Straif K, Grosse Y, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. The Lancet Oncology. 2003;4(6):552-553.

56. Van Hoft C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, Leufkens HG. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. International journal of cancer. 2000;87(4):591-594.

57. Rieck G, Fander A. The effect of lifestyle factors on gynaecological cancer. Best practice & research Clinical obstetrics & gynaecology. 2006;20(2):227-251.

58. Iyengar NM, Arthur R, Manson JE, Chlebowski RT, Kroenke CH, Peterson L, et al. Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. JAMA oncology. 2019;5(2):155-163.

59. O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, et al. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capcitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast cancer research and treatment. 2018;170(3):547-557.

60. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22.
Figures

Figure 1

Scatter plot for the effects of individual CRP-genetic instrumental variables on breast cancer risk. Each black dot reflects a genome-wide CRP-raising genetic variant. The blue lines indicate penalized weighted median estimates and 95% CIs. (CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IVW, inverse-variance weighted; MR, Mendelian randomization; PWM, penalized weighted median; SNP, single-nucleotide polymorphism.) A. Five genome-wide SNPs associated with high immune response and chronic inflammation (CRP > 3.0 mg/L) (PWM HR2nd-stage = 0.78, 95% CI: 0.52–1.16; MR-Egger intercept p value = 0.317). B. Fifty-six genome-wide SNPs associated with CRP phenotype that was naturally log-transformed (mg/L) (PWM HR2nd-stage = 0.91, 95% CI: 0.56–1.49; MR-Egger intercept p value = 0.391).
### Figure 2

Forest plot of MR estimates by E-only use. The plot shows the effects of genetically predicted chronic inflammation status (CRP > 3.0 mg/L) on breast cancer risk in E-only user subgroups, presented as the 95% CIs (red lines) of the estimates and the penalized weighted medians (percentages proportional to the size of the blue squares). The MR estimates were based on the SNP–breast cancer association that was adjusted for age and 10 principal components only. (CI, confidence interval; E, exogenous estrogen; HR, hazard ratio; MR, Mendelian randomization; PWM, penalized weighted median.)

| Mendelian randomization (MR): exogenous estrogen (E)-only use | PWM-HR (95%CI) | p | MR-Egger intercept: HR (95%CI) | p_Egger |
|------------------------------------------------------------|----------------|---|--------------------------------|---------|
| Nonusers                                                   | 1.09 (0.70,1.70) | 0.712 | 0.77 (0.47,1.26) | 0.188 |
| E-only use < 5 Years                                       | 0.40 (0.11,1.50) | 0.175 | 1.79 (0.34,9.34) | 0.345 |
| E-only use 5+ Years                                        | 0.31 (0.10,0.91) | 0.033 | 0.83 (0.15,4.51) | 0.755 |
| E-only use 10+ Years                                       | 0.15 (0.04,0.56) | 0.005 | 0.82 (0.08,8.54) | 0.804 |

### Figure 3

Forest plot of MR estimates by past OC use. The plot shows the effects of genetically predicted CRP phenotype on breast cancer risk in OC user subgroups, presented as the 95% CIs (red lines) of the estimates and the inverse-variance weights (percentages proportional to the size of the blue squares). The MR estimates were based on the SNP–breast cancer association that was adjusted for 1) only age and 10 principal components (PCs) in the first stage and 2)

| Mendelian randomization (MR): oral contraceptive past use | IVW-HR (95%CI), p | p-het | MR-Egger intercept: HR (95%CI), p |
|----------------------------------------------------------|--------------------|-------|---------------------------------|
| All SNPs                                                 |                    |       |                                 |
| < 5 years: the first stage                               | 0.79 (0.53,1.18)   | 0.250 | 0.97 (0.94,1.00) | 0.086 |
| : the second stage                                       | 0.78 (0.53,1.14)   | 0.192 | 0.97 (0.94,1.00) | 0.077 |
| 5+ years: the first stage                                | 2.00 (1.07,3.74)   | 0.029 | 1.01 (0.95,1.06) | 0.795 |
| : the second stage                                       | 2.08 (1.08,4.01)   | 0.029 | 1.01 (0.96,1.07) | 0.622 |
| After excluding pleiotropic SNPs                        |                    |       |                                 |
| < 5 years: the first stage                               | 0.84 (0.55,1.29)   | 0.419 | 0.97 (0.94,1.00) | 0.068 |
| : the second stage                                       | 0.83 (0.56,1.24)   | 0.365 | 0.97 (0.94,1.00) | 0.056 |
| 5+ years: the first stage                                | 2.08 (1.11,3.91)   | 0.023 | 0.99 (0.94,1.04) | 0.735 |
| : the second stage                                       | 2.14 (1.11,4.10)   | 0.023 | 1.00 (0.94,1.05) | 0.879 |
lifestyle covariates in addition to age and 10 PCs in the second stage. (CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IVW, inverse-variance weighted; MR, Mendelian randomization; OC, oral contraceptive; SNP, single-nucleotide polymorphism.)

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- TableS12020May30.docx
- TableS22020May30.docx
- TableS32020May30.docx
- TableS42020May30.docx
- TableS52020May30.docx